Johnson & Johnson is moving forward with its vaccine trials.
The company will begin a Phase 1/2a trial for its vaccine candidate on July 22 in Belgium and the following week in the United States, Dr. Paul Stoffels, chief scientific officer, said during an investor call on Thursday.
Stoffels said that Johnson & Johnson is also “in discussion with the National Institutes of Health with the objective to start Phase 3 clinical trials ahead of its original schedule, potentially in late September.”
The Phase 1/2a trials will include more than 1,000 healthy adults ages 18 to 55, as well as those 65 and older. The study will test the efficacy and safety of a single dose of the vaccine candidate, as well as a booster dose.
The results from the final study on the vaccine candidate in non-human primates is expected to be published “in a major scientific journal in the next coming weeks,” Stoffels added.